Gottlieb floats third class of drugs idea—again

Share this article:
American Enterprise Institute resident fellow and former FDA deputy Scott Gottlieb told a Drug Information Association conference in June that there is “fairly strong” sentiment within the agency favoring creation of a third, behind-the-counter (BTC) drug class between Rx and OTC.

However, he said, some physicians have raised safety issues, questioning whether consumers should self-medicate with products that are only available by prescription, and expressing doubts that appropriate patient monitoring is possible without medical supervision. He said another motive for physicians' opposition might be the prospect of losing revenues generated by repeat office calls for monitoring.

“Before FDA would consider a product for re-classification to OTC, for example,” he said, “the agency must be assured that the product has a favorable adverse event profile, and that use of the product requires no special monitoring.”

He said that these same criteria, if applied to BTC switch, might rule out switching products used to treat BPH (benign prostatic hyperplasia), as good medical practice dictates that patient screening for prostate cancer be accomplished prior to going on medications.

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...